Methods: IL-17 signaling deficient mice (Act1-/-) were infected with a clinical isolate of C. albicans in models of OPC and VVC. From day 1 post-infection (pi) through day 4 pi, mice were treated once daily via oral gavage with C-AMB or placebo or intraperitoneal AMB-deoxycholate (AMB-d). At day 5 pi, the mice were euthanized and tongue tissue (OPC) or vaginal fluid and vaginal tissue (VVC) were harvested to quantify fungal burden.
Results: During OPC, mice treated with C-AMB (25 or 83.5 mg/kg/day) displayed significantly reduced tongue fungal burden compared to placebo-treated mice and comparable to that observed in mice treated with intraperitoneal AMB-d (25 mg/kg/day). During VVC, mice treated with C-AMB exhibited significantly decreased fungal burden in vaginal tissue, but not vaginal fluid, relative to placebo-treated mice.
Conclusion: Oral administration of C-AMB in IL-17-signaling deficient mice results in a reduction in tongue and vaginal tissue fungal burden during mucosal C. albicans infections. Ongoing studies are aimed at characterizing the distribution of C-AMB in mouse mucosal tissues and examining C-AMB efficacy relative to fluconazole.
J. V. Desai,
A. F. Freeman, Matinas BioPharma Inc: Research Support , Research support .
E. Tramont, None
J. Jabbour, Matinas BioPharma Inc: Employee , Salary .
R. J. Mannino, Matinas BioPharma Inc: Employee , Salary .
M. S. Lionakis, Matinas BioPharma Inc: Research support , Research support .